Debate to Explore Whether the U.S. Scientific Enterprise Is Too Risk-Averse

Why It Matters

If federal research funding stifles high‑risk projects, the U.S. could lose its edge in breakthrough technologies, affecting economic growth and national security. The conversation also addresses declining public trust in science, a critical factor for policy support.

Key Takeaways

• Debate examines risk aversion in U.S. scientific funding and incentives
• Panel includes Tyler Cowen, Brandon Ogbunu, Kate Biberdorf, NSF director Panchanathan
• Event part of Hopkins Forum hosted by Niarchos Foundation Agora Institute
• Discussion highlights impact on innovation, public trust, and economic growth

Pulse Analysis

The United States’ post‑World War II research model—largely funded by federal agencies and channeled through universities, labs, and private firms—has powered historic breakthroughs from the internet to gene editing. Yet a growing chorus of scholars argues that the same mechanisms that guarantee steady progress may also penalize bold, high‑risk projects, favoring incremental work that fits established peer‑review criteria. This tension raises a fundamental policy question: how much risk should a publicly funded scientific system tolerate before it jeopardizes its own dynamism?

The upcoming Hopkins Forum debate brings together contrasting voices to probe that question. Economist Tyler Cowen and evolutionary biologist Brandon Ogbunu contend that entrenched funding streams and publication norms have created a “desert of progress,” slowing the pace of transformative discoveries. Opposing them, science communicator Kate Biberdorf and NSF director Sethuraman Panchanathan argue that the current system still delivers world‑leading outcomes, citing recent advances such as CRISPR and large‑language models that emerged from conventional grant pathways. Moderator John Donvan will steer the dialogue toward concrete examples, highlighting how risk‑averse cultures can sideline unconventional ideas while also safeguarding accountability for taxpayer dollars.

Beyond academic debate, the stakes are practical and political. A research ecosystem that shuns risk may cede leadership in emerging fields to nations with more adventurous funding approaches, eroding U.S. economic competitiveness and strategic security. Moreover, public confidence in science—already strained by politicization during the pandemic—depends on visible breakthroughs that address real‑world problems. Policymakers, university leaders, and the broader public will watch the outcome for clues on how to recalibrate incentives, perhaps by expanding venture‑style grants or reforming peer‑review processes, to ensure that bold science continues to drive growth and societal benefit.